15 results about "Tissue microarray" patented technology

The invention provides a construction method of a plant tissue space transcriptome sequencing library, which comprises the following steps: fixing and embedding plant tissues to obtain embedded blocks; performing autofluorescence detection and tissue permeabilization treatment on part of the embedded blocks, and determining an autofluorescence threshold value and target tissue permeabilization time; slicing, pasting and fixing the remaining embedding blocks, and performing microscope fluorescence scanning detection and tissue permeabilization treatment on the tissue-containing chip according to an autofluorescence threshold value and target tissue permeabilization time to obtain a permeabilized tissue chip; and carrying out reverse transcription, tissue removal, cDNA release, recovery and amplification on the permeabilized tissue chip to obtain a cDNA amplification product. The plant tissue transcript constructed by the construction method is not easy to diffuse and high in capture rate, high-quality in-situ capture time-space group data can be obtained, the accuracy and the credibility are high, the sequencing accuracy is ensured, and the application value is high.

The invention belongs to the field of neuroblastoma tissue analysis, and particularly discloses a child neuroblastoma tissue microarray chip and a preparation method thereof.The child neuroblastoma tissue microarray chip comprises a glass slide base material, and a plurality of neuroblastoma tissue samples arranged in a dot-matrix mode are arranged on the glass slide base material; by integrating a plurality of neuroblastoma samples including various pathological typing, grading and clinical staging types of neuroblastoma in a tissue block, efficient sample processing and analysis are achieved, comprehensiveness and representativeness of research are ensured, a large number of samples are analyzed simultaneously through a microarray technology, and the accuracy and accuracy of analysis are improved. The requirements for high-throughput screening of specific genes and expression proteins thereof in scientific research activities are met, the prediction capacity for tumor prognosis and the guidance accuracy for treatment schemes are improved, and neuroblastoma tissues are analyzed more efficiently and comprehensively.

In some embodiments, tissue microarray (TMA) core images are used to train a deep learning network that can then be deployed to computer inferences regarding whole tissue section (WTS) images (WSIs). Preprocessing aligns paired serial core images from differently stained core sections with their associated metadata and H-scores (or other label data obtained from evaluating one of the paired core sections). In some embodiment, a self-supervised learning (SSL) pre-trained encoder is used to generate patch-level embeddings from TMA core images associated with corresponding labels that are then used to train an attention-based deep learning network to generate inferences. These and other aspects of the present disclosure are more fully detailed herein.

The present invention discloses the application of CERS5 as a biomarker in the preparation of a detection agent for gastric cancer prognosis, belonging to the field of tumor molecular biology. The detection agent is used for detecting the level of CERS5 in samples of gastric cancer patients in the Asian population. The expression level of CerS5 is an independent influencing factor for the poor prognosis of gastric cancer in the Asian population. The present invention also provides the application of CERS5 as a biomarker in constructing a model for evaluating the prognosis of gastric cancer in gastric cancer patients, where the gastric cancer patients are gastric cancer patients in the Asian population. A tissue microarray is constructed from samples of gastric cancer patients in the Asian population; the expression of CERS5 in the tissue microarray is detected by immunohistochemistry; the H scoring system is used to evaluate the expression intensity of CERS5. If the CERS5 level in the sample of a gastric cancer patient > the critical value, it indicates a poor prognosis for the gastric cancer patient; if the CERS5 level in the sample of a gastric cancer patient ≤ the critical value, it indicates a good prognosis for the gastric cancer patient.

The utility model relates to a tissue chip dot matrix puncher which comprises a shell and a pushing assembly, the interior of the shell is hollow, sampling pipes are arranged on the front end face of the shell in an extending mode, each sampling pipe is of a tubular structure of a hollow structure, the multiple sampling pipes are arranged at intervals, and the pushing assembly comprises a pushing block and a pushing rod; the front end of the push rod is arranged in the shell, and the rear end of the push rod is a free end and extends outwards; the push block is arranged at the front end of the push rod, an insertion rod is arranged on the front end face of the push block and corresponds to the sampling tube in position, and the push block moves in the tube length direction of the sampling tube. The tissue chip dot matrix puncher has the advantages of high efficiency, accuracy, simplicity and convenience in operation and compact structure, and a high-quality solution is provided for punching treatment of tissue samples.

The embodiment of the invention discloses a manufacturing method of a pathological tissue microarray chip of a 3D cell model, a culture chip for preparing the 3D cell model is adopted for manufacturing, the culture chip is dried after being subjected to high-temperature and high-pressure sterilization, and low-adhesion treatment is performed for standby application; selecting a cell sample with a good growth state, and culturing a 3D cell model by utilizing the treated culture chip and the cell sample; directly performing embedding pretreatment on the 3D cell model in the culture chip to obtain a pre-embedded block comprising the 3D cell model; carrying out sample embedding treatment on the pre-embedded block by adopting OCT (Optical Coherence Tomography) glue to obtain a sample embedded block; and carrying out frozen section operation on the sample embedding block by adopting a freezing slicer to obtain the pathological tissue microarray chip. The steps of sample collection, transfer, centrifugation and the like can be omitted, the problems of sample loss, damage and the like are effectively avoided, the slicing operation is simplified, and the slicing efficiency is improved; besides, by utilizing array positioning of the culture micropores, the conditions of sample aggregation, deformation, extrusion damage, overlapping shielding and the like are avoided, and the requirements of visualization, data acquisition and statistics, spatial positioning and the like of sample monomers are met.

Disclosed are methods and systems for selecting one or more candidate regions from a tissue for inclusion in a tissue microarray (TMA). Methods involve determining tissue compositions of regions across the tissue and selecting the candidate regions that have desired tissue compositions for inclusion in a TMA. For example, desired tissue compositions can include one or more tissue classes, examples of which include tumor, stroma, immune, necrosis, other tissue, or combinations thereof. Thus, the disclosed method represents an automated process of selecting candidate regions without involving manual input.

The utility model relates to the technical field of paraffin tissue chips, and discloses paraffin tissue chip wax block manufacturing equipment which comprises a base, a limiting table is rotationally arranged above the base, a wax block mold is arranged on the limiting table, the wax block mold is connected with the limiting table in a sliding mode, a covering plate is arranged on the wax block mold, and the covering plate is connected with the limiting table in a sliding mode. A wax dissolving box is arranged beside the base, a heating stirring shaft is arranged in the wax dissolving box, the upper side of the wax dissolving box is connected with a wax feeding pipe, a wax feeding pump is connected between the wax feeding pipe and the wax dissolving box, one end of the wax feeding pipe is connected with a vacuum pump, the outlet end of the wax feeding pipe is connected with a flow dividing pipe, and a port of the flow dividing pipe is connected with an injection table assembly. Compared with the prior art, the wax block manufacturing device has the advantages that direct correlation between the wax block manufacturing quality and the experience level of an operator is avoided, the conditions that bubbles are generated on the wax block and the quality is uneven are reduced, the situation that the operator makes contact with a toxic reagent and hurt the body is reduced, and the situation that in the manufacturing process, liquid wax overflows, and the production efficiency is improved is avoided. The mold is difficult to clean.

The invention discloses an application of a glycosylated lysosomal membrane protein (GLMP) in preparation of a reagent for gastric cancer diagnosis, prognosis evaluation and treatment. Tissue microarray (TMA) immunohistochemical detection, cancer genome map (TCGA) data verification and clinical pathological characteristic and survival analysis prove that the GLMP is remarkably and highly expressed in GC tissues, and the high expression of the GLMP is related to the M stage and the TNM stage of a GC patient and can be used as an independent prognosis risk factor for predicting the adverse overall survival rate of the patient. Functional enrichment analysis shows that GLMP participates in immune related processes and extracellular matrix tissues, and is closely related to M2 type macrophage infiltration in an immunosuppressive tumor microenvironment. In-vitro experiments prove that the proliferation, migration and invasion ability of GC cells can be inhibited by knocking out the GLMP, and meanwhile, the polarization direction and chemotactic ability of macrophages are regulated and controlled. The molecular mechanism of the GLMP in GC is defined, a novel gastric cancer prognosis biomarker is provided, a novel target spot and strategy are provided for diagnosis, prognosis evaluation and targeted therapy of gastric cancer, and important clinical application value is achieved.

This topic discloses systems and methods for determining regions of interest (AOIs) for different types of input slides. Slide thumbnails can be assigned to one of five different types, and a separation algorithm for AOI detection is performed based on the slide type. Slide types include: ThinPrep (RTM) slides; Tissue Microarray (TMA) slides; Controlled HER2 slides with 4 cores; smear slides; and general-purpose slides. The slide type is specified based on user input. Customized AOI detection operations are provided for each slide type. If the user inputs an incorrect slide type, the operation includes detecting the incorrect input and performing an appropriate method. The result of each AOI detection operation provides a soft-weighted image as its output, with zero intensity values ​​at pixels detected as not belonging to tissue and higher intensity values ​​assigned to pixels detected as potentially belonging to tissue regions.

The present invention belongs to the field of biotechnology and discloses the use of CUL7 as a biomarker for the prognosis assessment of colorectal adenocarcinoma, specifically disclosing the use of CUL7 as a biomarker. The present invention uses bioinformatics and tissue microarrays (TMA) to explore the relationship between CUL7 expression and the prognosis and clinicopathological characteristics of colorectal adenocarcinoma (COAD). The results show that CUL7 expression is significantly increased in COAD tumor tissue compared to normal tissue. The K-M curve shows that in COAD, high CUL7 expression is associated with decreased survival, suggesting that CUL7 may be used as a biomarker for early screening or prognosis of colorectal adenocarcinoma and as a therapeutic target in clinical trials.

The invention belongs to the technical field of biological sample treatment, and particularly relates to a wax block remelting method of a tissue microarray chip. According to the technical scheme, the method comprises the steps that a to-be-treated wax block is placed in a quartz glass mold; the lower layer of the wax block is preheated, the heating temperature is controlled to be 65-70 DEG C, the heating lasts for 2-10 min, and heating is stopped when the wax block on the bottom layer is dissolved by 1-2 mm; standing and cooling to form a bottom solidified wax layer; the mold filled with the wax is transferred to a cooling table, and the temperature of the cooling table is controlled to range from-10 DEG C to-5 DEG C; meanwhile, heating the upper layer of the wax block by adopting a heating source; when the upper-layer wax block is completely melted and a 1-2mm unmelted wax layer is reserved on the lower-layer wax block, removing bubbles in the wax liquid by using a fine needle; covering the bottom support of the embedding box, and continuously standing the wax block on the cold table until the wax block is completely cured. The method is mainly used for providing a new choice for the wax block remelting method of the tissue microarray chip.

This invention provides an automated method and system for interpreting tissue microarray immunohistochemistry (IHC) results. The method includes acquiring and automatically cropping a full slide image, segmenting it into image blocks containing individual pathological samples, labeling target regions within the cropped image blocks to generate labeled data, which includes category information for positive and negative staining areas. After data processing, an optimized SOLOv2 instance segmentation model is trained using Dice Loss as the contour regression loss function and Focal Loss as the classification loss function to obtain a trained interpretation model. The trained interpretation model is then used to predict the image blocks at various points within the tissue microarray, outputting the immunohistochemical staining intensity grade and the percentage of positive cells for each image block, and automatically matching this with clinical information to generate structured results. This invention achieves standardized and objective interpretation of tissue microarray IHC slides, improving the consistency and efficiency of tissue microarray IHC interpretation.

An apparatus for facilitating quantitative anatomic pathology using mass spectrometry imaging includes a solid support having at least one flat surface, a tissue homogenate having a thickness mounted to the at least one flat surface of the solid support, and a quantitative array having a thickness and comprising a tissue microarray having a plurality of wells and a series of varying concentrations of an isotopically labeled metabolite deposited in the plurality of wells. The quantitative array is mounted over the tissue homogenate on the solid support.